Nan Fung Group Holdings Ltd
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$121.3M
Q ending 2026-03-31
Prior quarter
$111.7M
Q ending 2025-12-31
Change
+8.5% QoQ · -1.1% YoY
Positions
24
reported holdings
Largest positions
All 24 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Evommune Inc | EVMN | Shares | $33.1M | 1.4M |
| Maplight Therapeutics Inc | MPLT | Shares | $19.7M | 971K |
| Lb Pharmaceuticals Inc | LBRX | Shares | $15.6M | 631K |
| Oculis Holding Ag | Shares | $9.3M | 351K | |
| Incyte Corp | INCY | Shares | $5.1M | 54K |
| Beone Medicines Ltd | ONC | Shares | $4.7M | 16K |
| Rhythm Pharmaceuticals Inc | RYTM | Shares | $4.3M | 49K |
| Celcuity Inc | CELC | Shares | $3.2M | 28K |
| Ascendis Pharma A/S | Shares | $3.1M | 14K | |
| Procore Technologies Inc | PCOR | Shares | $3.0M | 53K |
| Madrigal Pharmaceuticals Inc | MDGL | Shares | $3.0M | 6K |
| Kymera Therapeutics Inc | KYMR | Shares | $2.6M | 31K |
| Acadia Pharmaceuticals Inc | ACAD | Shares | $2.3M | 103K |
| Cybin Inc | HELP | Shares | $2.2M | 460K |
| Argenx Se | ARGX | Shares | $2.0M | 3K |
| Revolution Medicines Inc | RVMD | Shares | $1.9M | 19K |
| Recursion Pharmaceuticals In | RXRX | Shares | $1.8M | 595K |
| Insmed Inc | INSM | Shares | $1.1M | 7K |
| Ishares Ethereum Tr | ETHA | Shares | $800K | 51K |
| Harmony Biosciences Hldgs In | HRMY | Shares | $758K | 27K |
| Entrada Therapeutics Inc | TRDA | Shares | $619K | 49K |
| Ishares Bitcoin Trust Etf | IBIT | Shares | $613K | 16K |
| Rani Therapeutics Hldgs Inc | RANI | Shares | $363K | 494K |
| Bolt Biotherapeutics Inc | BOLT | Shares | $118K | 29K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.